{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:15:48Z","timestamp":1790982948806,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2005,5]]},"DOI":"10.1016\/j.amjcard.2005.03.003","type":"journal-article","created":{"date-parts":[[2005,4,20]],"date-time":"2005-04-20T11:28:41Z","timestamp":1113996521000},"page":"8-13","source":"Crossref","is-referenced-by-count":154,"special_numbering":"S1","title":["Neurohormonal Activation in Congestive Heart Failure and the Role of Vasopressin"],"prefix":"10.1016","volume":"95","author":[{"given":"Kanu","family":"Chatterjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2005.03.003_bib1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00129784-200303010-00002","article-title":"Vasopressin receptor antagonists: therapeutic potential in the management of acute and chronic heart failure","volume":"3","author":"Russell","year":"2003","journal-title":"Am J Cardiovasc Drugs"},{"issue":"suppl 4","key":"10.1016\/j.amjcard.2005.03.003_bib2","first-page":"80","article-title":"Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure","volume":"75","author":"Packer","year":"1987","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2005.03.003_bib3","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.coph.2003.06.005","article-title":"Vasopressin receptor antagonists in heart failure","volume":"3","author":"Thibonnier","year":"2003","journal-title":"Curr Opin Pharamacol"},{"key":"10.1016\/j.amjcard.2005.03.003_bib4","unstructured":"Braunwald Atlas of Heart Diseases Online [book online]. Available at: http:\/\/www.norvasc-braunwald.com\/index.asp. Accessed February 24, 2005."},{"key":"10.1016\/j.amjcard.2005.03.003_bib5","unstructured":"Paganelli WC, Creager MA, Dzau VJ. Cardiac regulation of kidney function. In: Cheng TO, ed. The International Textbook of Cardiology. New York: Pergamon Press, 1986:1010\u20131020."},{"key":"10.1016\/j.amjcard.2005.03.003_bib6","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0008-6363(01)00297-8","article-title":"Water and sodium regulation in chronic heart failure: the role of natriuretic peptides and vasopressin","volume":"51","author":"Kalra","year":"2001","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.amjcard.2005.03.003_bib7","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1161\/01.CIR.82.5.1724","article-title":"Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD)","volume":"82","author":"Francis","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2005.03.003_bib8","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1161\/01.CIR.82.5.1730","article-title":"Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality","volume":"82","author":"Swedberg","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2005.03.003_bib9","doi-asserted-by":"crossref","unstructured":"Beta Blocker Heart Attack Trial Study Group. A randomized study of propranolol in patients with myocardial infarction: mortality results. JAMA 1982;247:1707\u20131714.","DOI":"10.1001\/jama.1982.03320370021023"},{"key":"10.1016\/j.amjcard.2005.03.003_bib10","first-page":"852","article-title":"Selective vasopressin, angiotensin II, or dual receptor blockade with developing congestive heart failure","volume":"293","author":"Clair","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.amjcard.2005.03.003_bib11","first-page":"3140","article-title":"Angiotensin-II receptor antagonists: their place in therapy","volume":"59","author":"Kirk","year":"1999","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.amjcard.2005.03.003_bib12","series-title":"The edematous patient: cardiac failure, cirrhosis, and nephrotic syndrome","author":"Ellison","year":"2000"},{"key":"10.1016\/j.amjcard.2005.03.003_bib13","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1210\/en.2003-0150","article-title":"Minireview: overview of the renin-angiotensin system\u2014an endocrine and paracrine system","volume":"144","author":"Lavoie","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.amjcard.2005.03.003_bib14","unstructured":"Craig S. Hyponatremia. Available at: http:\/\/www.emedicine.com\/emerg\/topic275.htm. Accessed November 16, 2004."},{"key":"10.1016\/j.amjcard.2005.03.003_bib15","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S0735-1097(86)80333-3","article-title":"Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: comparison with the renin-angiotensin system and the sympathetic nervous system","volume":"7","author":"Creager","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2005.03.003_bib16","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1161\/01.CIR.0000014763.63528.9D","article-title":"New therapeutic options in congestive heart failure: part I","volume":"105","author":"McMurray","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2005.03.003_bib17","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S1521-690X(03)00049-6","article-title":"Disorders of body water homeostasis","volume":"17","author":"Verbalis","year":"2003","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.amjcard.2005.03.003_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/CS20030062","article-title":"Therapeutic role of vasopressin receptor antagonism in patients with liver cirrhosis","volume":"105","author":"Ferguson","year":"2003","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.amjcard.2005.03.003_bib19","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev.pharmtox.41.1.175","article-title":"The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists","volume":"41","author":"Thibonnier","year":"2001","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.amjcard.2005.03.003_bib20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0002-8703(02)94708-3","article-title":"Vasopressin: a new target for the treatment of heart failure","volume":"146","author":"Lee","year":"2003","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2005.03.003_bib21","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1681\/ASN.V103647","article-title":"Physiology and pathophysiology of renal aquaporins","volume":"10","author":"Nielsen","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjcard.2005.03.003_bib22","series-title":"Textbook of Medical Physiology","first-page":"308","article-title":"The kidneys and body fluids","author":"Guyton","year":"1996"},{"key":"10.1016\/j.amjcard.2005.03.003_bib23","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0735-1097(83)80040-0","article-title":"Increased plasma arginine vasopressin levels in patients with congestive heart failure","volume":"1","author":"Goldsmith","year":"1983","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2005.03.003_bib24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1056\/NEJM198107303050506","article-title":"Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure","volume":"305","author":"Szatalowicz","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2005.03.003_bib25","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1172\/JCI119312","article-title":"Upregulation of aquaporin-2 water channel expression in chronic heart failure rat","volume":"99","author":"Xu","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjcard.2005.03.003_bib26","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0735-1097(86)80417-X","article-title":"Hemodynamic effects of infused arginine vasopressin in congestive heart failure","volume":"8","author":"Goldsmith","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2005.03.003_bib27","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0014-2999(99)00004-7","article-title":"Vasopressin increases vascular endothelial growth factor secretion from human vascular smooth muscle cells","volume":"368","author":"Tahara","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.amjcard.2005.03.003_bib28","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s004240050772","article-title":"AVP-induced mitogenic responses of Chinese hamster ovary cells expressing human V1A or V1B receptors","volume":"437","author":"Tahara","year":"1999","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.amjcard.2005.03.003_bib29","first-page":"546","article-title":"Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men","volume":"272","author":"Ohnishi","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.amjcard.2005.03.003_bib30","doi-asserted-by":"crossref","first-page":"259S","DOI":"10.1111\/j.1469-445X.2000.tb00031.x","article-title":"Vasopressin receptor antagonism: a therapeutic option in heart failure and hypertension","volume":"85S","author":"Burrell","year":"2000","journal-title":"Exp Physiol"},{"key":"10.1016\/j.amjcard.2005.03.003_bib31","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0196-9781(02)00138-9","article-title":"Effect of YM471, a nonpeptide AVP receptor antagonist, on human coronary artery smooth muscle cells","volume":"23","author":"Tahara","year":"2002","journal-title":"Peptides"},{"key":"10.1016\/j.amjcard.2005.03.003_bib32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0008-6363(02)00244-4","article-title":"Neurohormonal antagonism in heart failure: beneficial effects of vasopressin V1a and V2 receptor blockade and ACE inhibition","volume":"54","author":"Naitoh","year":"2002","journal-title":"Cardiovasc Res"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914905003541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914905003541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T09:31:55Z","timestamp":1625823115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914905003541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["S0002914905003541"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2005.03.003","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2005,5]]}}}